Myocardial Fibrosis Severity on Cardiac Magnetic Resonance Imaging Predicts Sustained Arrhythmic Events in Hypertrophic Cardiomyopathy

Canadian Journal of Cardiology

Volumn 29, Issue 3, 2013, Pages 358-363

  Prinz, Christian ^a   Schwarz, Maria ^a   Ilic, Ivan ^b   Laser, Kai Thorsten ^a   Lehmann, Roman ^a   Prinz, Eva Maria ^a   Bitter, Thomas ^a   Vogt, Jürgen ^a   Van Buuren, Frank ^a   Bogunovic, Nikola ^a   Horstkotte, Dieter ^a   Faber, Lothar ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART MUSCLE FIBROSIS; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; SUDDEN DEATH; ULTRASOUND SCANNER;

ADULT; AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, HYPERTROPHIC; COHORT STUDIES; CONTRAST MEDIA; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; GADOLINIUM; GERMANY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 84874319772     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.05.004     Document Type: Article

References (32)

1. Maron B.J. Hypertrophic cardiomyopathy: an important global disease. Am J Med 2004, 116:63-65.
2. Zou Y., Song L., Wang Z., et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population based echocardiography analysis of 8080 adults. Am J Med 2004, 116:14-18.
3. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003, 42:1687-1713.
4. Maron B.J., Seidman C.E., Ackerman M.J., et al. How should hypertrophic cardiomyopathy be classified?. What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. Circ Cardiovasc Genet 2009, 2:81-85.
5. Harris K.M., Spirito P., Maron M.S., et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006, 114:216-225.
6. Maron M.S., Olivotto I., Betocchi S., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003, 348:295-303.
7. Cecchi F., Maron B.J., Epstein S.E. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989, 13:1283-1288.
8. Elliott P.M., Sharma S., Vamava A., et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999, 33:1596-1601.
9. Elliott P.M., Poloniecki J., Dickie S., et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000, 36:2212-2218.
10. Maron B.J., Olivotto I., Bellone P., et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 39:301-307.
11. Olivotto I., Cecchi F., Casey S.A., et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001, 104:2517-2524.
12. Spirito P., Autore C., Rapezzi C., et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009, 119:1703-1710.
13. Maron B.J., Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2008, 19:1118-1126.
14. Maron B.J., Spirito P., Shen W.K., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007, 298:405-412.
15. Maron B.J., Shen W.K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000, 342:365-373.
16. Kwon D.H., Smedira N.G., Rodriguez E.R., et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence or ventricular tachycardia. J Am Coll Cardiol 2009, 54:242-249.
17. de Bakker J.M., van Capelle F.J., Janse M.J., et al. Slow conduction in the infarcted human heart. 'Zigzag' course of activation. Circulation 1993, 88:915-926.
18. Adabag A.S., Maron B.J., Appelbaum E., et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008, 51:1369-1374.
19. Maron M.S., Appelbaum E., Harrigan C.J., et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008, 1:184-191.
20. Moon J.C., McKenna W.J., McCrohon J.A., et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41:1561-1567.
21. Rubinshtein R., Glockner J.F., Ommen S.R., et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010, 3:51-58.
22. O'Hanlon R., Grasso A., Roughton M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:867-874.
23. Popescu B.A., Andrade M.J., Badano L.P., et al. European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. Eur J Echocardiogr 2009, 10:893-905.
24. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006, 7:79-108. American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology.
25. Cerqueira M.D., Weissman N.J., Dilsizian V., et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging 2002, 18:539-542.
26. Almquist A.K., Montgomery J.V., Haas T.S., et al. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm 2005, 2:814-819.
27. Boriani G., Maron B.J., Shen W.-K., et al. Prevention of sudden death in hypertrophic cardiomyopathy: but which defibrillator for which patient?. Circulation 2004, 110:438-442.
28. Gersh B.J., Maron B.J., Bonow R.O., et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 124:e153-e203.
29. Bruder O., Wagner A., Jensen C.J., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:875-887.
30. Fluechter S., Kuschyk J., Wolpert C., et al. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2010, 12:30.
31. Moon J.C., McKenna W.J., McCrohon J.A., et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41:1561-1567.
32. Noureldin R.A., Liu S., Nacif M.S., et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012, 20:14-17.